CA2139503A1 - Composes pour le traitement et l'imagerie dans les cas de cancer - Google Patents

Composes pour le traitement et l'imagerie dans les cas de cancer

Info

Publication number
CA2139503A1
CA2139503A1 CA002139503A CA2139503A CA2139503A1 CA 2139503 A1 CA2139503 A1 CA 2139503A1 CA 002139503 A CA002139503 A CA 002139503A CA 2139503 A CA2139503 A CA 2139503A CA 2139503 A1 CA2139503 A1 CA 2139503A1
Authority
CA
Canada
Prior art keywords
compound
independently
lower alkyl
halo
heterocyclic ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002139503A
Other languages
English (en)
Inventor
Christy S. John
Jesse Baumgold
John G. Mcafee
Terry W. Moody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP6525353A priority Critical patent/JPH08510235A/ja
Priority to PCT/US1993/004309 priority patent/WO1994026314A1/fr
Priority to CA002139503A priority patent/CA2139503A1/fr
Priority to EP94930839A priority patent/EP0650372A4/fr
Publication of CA2139503A1 publication Critical patent/CA2139503A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0419—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
CA002139503A 1993-05-06 1993-05-06 Composes pour le traitement et l'imagerie dans les cas de cancer Abandoned CA2139503A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP6525353A JPH08510235A (ja) 1993-05-06 1993-05-06 癌の撮像及び治療用化合物
PCT/US1993/004309 WO1994026314A1 (fr) 1993-05-06 1993-05-06 Composes destines a la visualisation et a la therapie du cancer
CA002139503A CA2139503A1 (fr) 1993-05-06 1993-05-06 Composes pour le traitement et l'imagerie dans les cas de cancer
EP94930839A EP0650372A4 (fr) 1993-05-06 1993-05-06 Composes destines a la visualisation et a la therapie du cancer.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1993/004309 WO1994026314A1 (fr) 1993-05-06 1993-05-06 Composes destines a la visualisation et a la therapie du cancer
CA002139503A CA2139503A1 (fr) 1993-05-06 1993-05-06 Composes pour le traitement et l'imagerie dans les cas de cancer

Publications (1)

Publication Number Publication Date
CA2139503A1 true CA2139503A1 (fr) 1994-11-24

Family

ID=4154976

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002139503A Abandoned CA2139503A1 (fr) 1993-05-06 1993-05-06 Composes pour le traitement et l'imagerie dans les cas de cancer

Country Status (4)

Country Link
EP (1) EP0650372A4 (fr)
JP (1) JPH08510235A (fr)
CA (1) CA2139503A1 (fr)
WO (1) WO1994026314A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993777A (en) * 1993-05-06 1999-11-30 Research Corporation Technologies, Inc. Benzamide compounds for cancer imaging and therapy
US5911970A (en) * 1993-05-06 1999-06-15 Research Corporation Technologies, Inc. Methods for cancer imaging and therapy using benzamine compounds
US6517811B2 (en) 1993-05-06 2003-02-11 Research Corporation Technologies, Inc. Compounds for cancer imaging and therapy
GB9507882D0 (en) * 1995-04-18 1995-05-31 Pharmacia Spa Substituted dihydrobenzofuran derivatives as 5-ht4 agonists
US5919934A (en) * 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy
US7659400B2 (en) 2003-07-31 2010-02-09 Washington University Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging
DE102004011720B4 (de) 2004-03-10 2008-04-03 Bayer Schering Pharma Aktiengesellschaft Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
CN109721533A (zh) * 2017-10-27 2019-05-07 华中科技大学同济医学院附属协和医院 靶向黑色素瘤的显像剂及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591634A (en) * 1967-06-20 1971-07-06 Ile De France N-(tertiary amino-alkyl)-benzamides
US3891671A (en) * 1968-08-01 1975-06-24 Ile De France N-(2-pyrrolidyl or piperidyl alkyl)-4-hydroxy benzamides
FR2440946A2 (fr) * 1978-01-20 1980-06-06 Ile De France Nouveaux benzamides heterocycliques substitues, leurs procedes de preparation et leur application comme modificateurs du comportement
US4360511A (en) * 1978-11-29 1982-11-23 Medi-Physics, Inc. Amines useful as brain imaging agents
US4584187A (en) * 1981-04-01 1986-04-22 Wieland Donald M Imaging agent and method of use
US4430319A (en) * 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
US4647446A (en) * 1982-08-18 1987-03-03 The Regents Of The University Of California Rapid brain scanning radiopharmaceutical
SE8205135D0 (sv) * 1982-09-09 1982-09-09 Astra Laekemedel Ab Benzamido-derivatives
US4888353A (en) * 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
US5154913A (en) * 1987-11-19 1992-10-13 Vanderbilt University Radioiodinated benzamines method of their use as radioimaging agents
FR2642972B1 (fr) * 1989-02-14 1994-08-05 Inst Nat Sante Rech Med Agents pour le diagnostic et le traitement des melanomes, derives halogenes aromatiques utilisables comme de tels agents et leur preparation
US5122361A (en) * 1989-04-17 1992-06-16 Trustees Of The University Of Pennsylvania Dopamine receptor ligands and imaging agents

Also Published As

Publication number Publication date
EP0650372A4 (fr) 1996-07-03
EP0650372A1 (fr) 1995-05-03
WO1994026314A1 (fr) 1994-11-24
JPH08510235A (ja) 1996-10-29

Similar Documents

Publication Publication Date Title
US6517811B2 (en) Compounds for cancer imaging and therapy
TW449482B (en) Radiolabeled peptides for diagnosis and therapy
Kung et al. Dopamine D-2 receptor imaging radiopharmaceuticals: Synthesis, radiolabeling and in vitro binding of (R)-(+)-and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl] benzamide
ES2700234T3 (es) Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
US4994258A (en) Gamma emitting, CCK-A antagonists for pancreatic imaging
US6447748B1 (en) Benzamide compounds for cancer imaging and therapy
CN118955616B (zh) 一种靶向结合成纤维细胞活化蛋白化合物及应用
Drews et al. Synthesis and biological evaluation of technetium (III) mixed-ligand complexes with high affinity for the cerebral 5-HT1A receptor and the alpha1-adrenergic receptor
John et al. Synthesis, in vitro binding, and tissue distribution of radioiodinated 2-[125I] N-(N-benzylpiperidin-4-yl)-2-iodo benzamide, 2-[125I] BP: A potential σ receptor marker for human prostate tumors
CN115010629B (zh) 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
CA2139503A1 (fr) Composes pour le traitement et l'imagerie dans les cas de cancer
US5919934A (en) Compounds, compositions, and methods for cancer imaging and therapy
CN109985252A (zh) 一种新型双模态小分子造影剂及其制备方法与应用
John et al. Synthesis, in vitro validation and in vivo pharmacokinetics of [125I] N-[2-(4-iodophenyl) ethyl]-N-methyl-2-(1-piperidinyl) ethylamine: a high-affinity ligand for imaging sigma receptor positive tumors
John et al. An improved synthesis of [125I] N-(diethylaminoethyl)-4-iodobenzamide: a potential ligand for imaging malignant melanoma
AU2015203742A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
US5993777A (en) Benzamide compounds for cancer imaging and therapy
US20250152758A1 (en) Probe for nuclear medical testing
JP4951798B2 (ja) 側基脂肪酸撮像剤
EP1867634B1 (fr) Ligand pour le transporteur d acetylcholine vesiculaire
CN119751415B (zh) 双靶向PSMA和FAP-α的前列腺癌诊断或治疗放射性药物
US11701439B2 (en) DAZA chelators as ligands in liver imaging
Yue et al. Site-specific π-clamp-mediated radiosynthesis of 68 Ga and 18 F PET radiopharmaceuticals
US20050026974A1 (en) Detection of hypoxia
Hanson et al. Preparation and biodistribution of a 125I-labeled β-adrenoceptor antagonist bearing a cardioselectivity-enhancing N-substituent

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20050406